These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31502653)

  • 1. Pleural Fluid Eosinophilia: A Possible Adverse Event of Interleukin-17 Inhibition.
    Hayashi W; Osada SI; Toyoshima A; Yamada K; Sudo K; Nakayama K; Manabe M
    Acta Derm Venereol; 2019 Nov; 99(12):1174-1175. PubMed ID: 31502653
    [No Abstract]   [Full Text] [Related]  

  • 2. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis.
    Teraki Y; Takahashi A; Inoue Y; Takamura S
    Acta Derm Venereol; 2018 Apr; 98(4):456-457. PubMed ID: 29327064
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience.
    Conti A; Peccerillo F; Amerio P; Balato A; Bardazzi F; Bianchi L; Burlando M; Cannavò SP; Chiricozzi A; Dapavo P; De Simone C; Fargnoli MC; Gambardella A; Gisondi P; Malagoli P; Malara G; Mugheddu C; Offidani AM; Piaserico S; Prignano F; Stingeni L; Pellacani G
    Br J Dermatol; 2019 Jun; 180(6):1547-1548. PubMed ID: 30578668
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis.
    Romiti R; Valenzuela F; Chouela EN; Xu W; Pangallo B; Moriarty SR; Gürbüz S; Riedl E
    Br J Dermatol; 2019 Jul; 181(1):202-203. PubMed ID: 30609008
    [No Abstract]   [Full Text] [Related]  

  • 6. Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumab.
    Smith SD; Conrad C; Ramharter M; Gottlieb AB; Patel H; Xu W; Riedl E; Schuster C
    J Am Acad Dermatol; 2020 Jul; 83(1):261-263. PubMed ID: 32092375
    [No Abstract]   [Full Text] [Related]  

  • 7. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition.
    Napolitano M; Megna M; Fabbrocini G; Nisticò SP; Balato N; Dastoli S; Patruno C
    Br J Dermatol; 2019 Sep; 181(3):604-606. PubMed ID: 30768788
    [No Abstract]   [Full Text] [Related]  

  • 8. Broadalumab (Siliq)--another IL-17A antagonist for psoriasis.
    Med Lett Drugs Ther; 2017 Jul; 59(1525):118-119. PubMed ID: 28699932
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: A single-center experience.
    Ohata C; Ohyama B; Katayama E; Nakama T
    J Dermatol; 2020 Apr; 47(4):405-408. PubMed ID: 31994229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Kimura R; Sugita K; Yamamoto O
    Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034
    [No Abstract]   [Full Text] [Related]  

  • 11. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed.
    Kimmel G; Chima M; Kim HJ; Bares J; Yao CJ; Singer G; Kim SJ; Bagel J; Lebwohl M
    J Am Acad Dermatol; 2019 Sep; 81(3):857-859. PubMed ID: 31078609
    [No Abstract]   [Full Text] [Related]  

  • 12. Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases.
    Pinter A; Wilsmann-Theis D; Peitsch WK; Mössner R
    J Dermatol; 2019 May; 46(5):426-430. PubMed ID: 30786053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ixekizumab (Taltz)--a second IL-17A inhibitor for psoriasis.
    Med Lett Drugs Ther; 2016 May; 58(1494):59-60. PubMed ID: 27148922
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug survival, effectiveness, and safety of brodalumab for moderate-to-severe psoriasis up to 3 years.
    Mastorino L; Dapavo P; Burzi L; Rosset F; Giunipero di Corteranzo I; Leo F; Verrone A; Stroppiana E; Ortoncelli M; Ribero S; Quaglino P
    Int J Dermatol; 2024 Jul; 63(7):922-928. PubMed ID: 38284277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal.
    Danset M; Hacard F; Jaulent C; Nosbaum A; Berard F; Nicolas JF; Goujon C
    Eur J Dermatol; 2020 Dec; 30(6):741-743. PubMed ID: 33337328
    [No Abstract]   [Full Text] [Related]  

  • 16. IL-17 inhibitors for psoriasis.
    Paek SY; Frieder J; Kivelevitch D; Menter MA
    Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutics: Silencing psoriasis.
    Crow JM
    Nature; 2012 Dec; 492(7429):S58-9. PubMed ID: 23254974
    [No Abstract]   [Full Text] [Related]  

  • 18. [Monoclonal antibodies targeting IL-17A or its receptor in psoriasis: a new therapeutic approach?].
    Bonnet MC; Bagot M; Bensussan A
    Med Sci (Paris); 2012 Dec; 28(12):1035-7. PubMed ID: 23290394
    [No Abstract]   [Full Text] [Related]  

  • 19. Three cases of facial erythema with dryness and pruritus in psoriasis patients during treatment with IL-17 inhibitors.
    Oiwa T; Honda T; Otsuka A; Kabashima K
    J Eur Acad Dermatol Venereol; 2018 Apr; 32(4):e122-e123. PubMed ID: 28983980
    [No Abstract]   [Full Text] [Related]  

  • 20. Two cases of skin infection during psoriasis treatment with brodalumab.
    Kobayashi M; Nagata M; Oaku S; Kanda N; Tada Y; Aozasa N
    J Dermatol; 2018 Mar; 45(3):e51-e52. PubMed ID: 29083051
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.